Evaluation of the effectiveness of a self-help smartphone app for aftercare among patients with depressive symptoms: a randomized controlled trial

Evaluation of the effectiveness of a self-help smartphone app for aftercare among patients with depressive symptoms: a randomized controlled trial - MCT & More-Aftercare

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00022559

Enrollment

149

Registered

2020-12-09

Start date

2020-10-12

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32

Interventions

Group 1: Interventional: self-help smartphone app for depressive symptoms. The "MCT & More" app contains 97 short exercises on the following topics: cognitive strategies, communication and interactio

using regular outpatient care during the intervention period is permitted.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: at least 18 years old, a psychiatric diagnosis according to ICD-10 (exclusion: dementia), upcoming discharge after inpatient treatment or day-care in a psychiatric hospital (baseline assessment max. 1 week before discharge), informed consent, internet access and smartphone, willingness to participate in two online surveys (approx. 30 minutes each), willingness to take part in the four-week smartphone intervention, willingness to use the smartphone intervention on one's own responsibility, willingness to leave an anonymous e-mail address for the survey, presence of depressive symptoms (measured by PHQ-9), no acute suicidal tendencies (measured by PHQ9, item 9)

Exclusion criteria

Exclusion criteria: Exclusion: dementia, acute suicidal tendencies

Design outcomes

Primary

Measure	Time frame
The Rosenberg Self-Esteem Scale (RSE) is used as the primary outcome parameter to measure self-esteem (at T0 and T1 after 4 weeks).	—

Secondary

Measure	Time frame
The Patient Health Questionnaire - 9 Depression Module (PHQ-9) to assess the severity of the depressive symptoms and a Globalitem of the World Health Organization Quality of Life - abbreviated version (WHOQOL-BREF) to measure the quality of life (T0 and T1 after 4 weeks) serve as secondary success parameters. In addition, the Attitude Towards Psychological Online Interventions Questionnaire (APOI), the Patientenfragebogen zur Therapieerwartung und Therapieevaluation (PATHEV), socio-demographic data and therapy experiences are assessed at T0. Possible side effects via the Inventar zur Erfassung negativer Effekte von Psychotherapie (INEP) and patient satisfaction via the Fragebogen zur Messung der Patientenzufriedenheit (ZUF-8) will be assessed at T1 (after 4 weeks).	—

Measure

Time frame

The Patient Health Questionnaire - 9 Depression Module (PHQ-9) to assess the severity of the depressive symptoms and a Globalitem of the World Health Organization Quality of Life - abbreviated version (WHOQOL-BREF) to measure the quality of life (T0 and T1 after 4 weeks) serve as secondary success parameters. In addition, the Attitude Towards Psychological Online Interventions Questionnaire (APOI), the Patientenfragebogen zur Therapieerwartung und Therapieevaluation (PATHEV), socio-demographic data and therapy experiences are assessed at T0. Possible side effects via the Inventar zur Erfassung negativer Effekte von Psychotherapie (INEP) and patient satisfaction via the Fragebogen zur Messung der Patientenzufriedenheit (ZUF-8) will be assessed at T1 (after 4 weeks).

—

Countries

Germany

Contacts

Public ContactSteffen Moritz

Universitätsklinikum Hamburg-EppendorfKlinik und Poliklinik für Psychiatrie und PsychotherapieArbeitsgruppe Klinische Neuropsychologie

moritz@uke.de+49 40 7410 56565

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 10, 2026